Precision BioSciences, Inc. - DTIL STOCK NEWS

Precision BioSciences, Inc. (Nasdaq: DTIL) will report its first quarter 2021 financial results and provide a business update on May 13, 2021. The company focuses on developing innovative allogeneic CAR T and in vivo gene correction therapies utilizing its proprietary ARCUS^® genome editing platform. This platform aims to enhance therapeutic safety and control, targeting genetic and infectious diseases for which current treatments are inadequate.

Precision BioSciences, Inc. (Nasdaq: DTIL) announced a preclinical study presentation at the ARVO Annual Meeting, focusing on ARCUS genome editing for autosomal dominant Retinitis Pigmentosa (adRP). The study demonstrates that ARCUS can rejuvenate rod photoreceptor structure and function in a pig model with the common P23H rhodopsin mutation. Significant improvements in rod-driven signals were observed, suggesting potential for late-stage treatment in humans. This research adds to growing preclinical support for ARCUS in addressing rare genetic conditions.

Precision BioSciences, Inc. (Nasdaq: DTIL) announced a poster presentation at the ASGCT Annual Meeting, scheduled for May 11-14, 2021. The poster titled "Translation of an AAV-delivered gene editing approach for transthyretin amyloidosis in animal models" will be presented by Dr. Jenny A. Greig from the University of Pennsylvania. This research highlights the use of ARCUS gene editing in treating transthyretin amyloidosis, a disease caused by misfolded transthyretin protein. Initial findings indicate a successful knock-out of the TTR gene, showing promise for permanent genomic edits.

Precision BioSciences has appointed Dr. Alan List as Chief Medical Officer, enhancing its leadership team. Dr. List brings significant expertise in hematology and oncology, having led clinical programs for multiple FDA-approved drugs. He will oversee the development of allogeneic CAR T therapies, including the lead therapy PBCAR0191 and next-gen PBCAR19B. Dr. List's prior role as a strategic advisor will support a smooth transition from outgoing CMO Chris Heery, who will remain as a consultant. This appointment comes as Precision progresses with several clinical trials.

Precision BioSciences (NASDAQ: DTIL) has reacquired global development and commercialization rights for its allogeneic CAR T programs from Servier, encompassing PBCAR0191, PBCAR19B, and four other targets. The transaction, valued at $1.25 million plus waived milestone payments of $18.75 million, enhances Precision's control over its clinical pipeline. CEO Matt Kane highlighted the promising nature of these CD19-targeting candidates, particularly PBCAR0191, which continues to yield favorable clinical results. The company expects sufficient cash reserves into 2023, facilitating ongoing operations.

Precision BioSciences, Inc. (Nasdaq: DTIL) announces the appointment of Dr. Stanley R. Frankel as a Director and member of the Science and Technology Committee. Dr. Frankel, a seasoned hematologist-oncologist, brings extensive experience in immuno-oncology and cellular therapies, having led programs for multiple FDA-approved drugs. His leadership is expected to aid Precision in advancing its CAR T and gene correction therapies. Dr. Tony Yao will continue his board term until May 10, 2021, after supporting the company through its transition to a public entity.

Precision BioSciences Inc. (Nasdaq: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.

Event Details:
Date: April 13, 2021
Time: 11:00 AM ET
A live webcast will be available on the company's website under the Investors & Media section, with a replay for approximately 30 days following the event.

Precision BioSciences focuses on developing innovative therapies using its proprietary ARCUS® genome editing platform.

Precision BioSciences (Nasdaq: DTIL) announced a transition plan to recruit a new Chief Executive Officer, with current CEO Matt Kane remaining in his role until a successor is found. The management team aims to advance CAR T programs, direct research against specific gene targets, and validate gene editing initiatives. While thanking Kane for his contributions, the board emphasizes the importance of identifying a leader to navigate the company's next growth phase and maximize opportunities within the ARCUS platform.

Precision BioSciences (Nasdaq: DTIL) announced its participation in the Guggenheim Healthcare Talks 2021 on April 1, 2021, focusing on genomic medicines and rare diseases. Dr. Derek Jantz, Chief Scientific Officer, will present on advancements in genomic medicine and cell therapy for dyslipidemia and Type 1 diabetes mellitus. The presentation will take place from 8:00-8:50 AM ET and will be accessible via a live webcast on the company's website, with an archived replay available for 30 days.